Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, et al
Studies use the CJC-1295 Without DAC + Ipamorelin combination to examine the interaction between GHS-R1a activation, somatostatin pathway suppression, and GHRH-R co-stimulation in determining GH pulse amplitude and somatostatin-override capacity
Why Stack CJC 1295 and Ipamorelin
GHRH (Growth Hormone-Releasing Hormone) Produced by the hypothalamus, GHRH travels through the hypophyseal portal system to stimulate the anterior pituitary to release GH
Clinical trials show that a proportion of weight lost on these medications, typically around 25 to 40%, can be lean mass rather than fat
The certainty of results is moderate, suggesting a potential benefit of L-carnitine as an adjunct to PDE5 inhibitors in this population